GlassScriptPhysician profile
Jason J Suh
NPI 1225024722
$65,411.38
in general payments reported to CMS, 2019-2025
60 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $5,644 · 2021: $14K · 2022: $9,070 · 2023: $2,984 · 2024: $5,020 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,150 · Travel and Lodging: $2,244 · Honoraria: $1,500 · Food and Beverage: $836 · Education: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,150.00 |
| Travel and Lodging | $2,243.82 |
| Honoraria | $1,500.00 |
| Food and Beverage | $835.78 |
| Education | $374.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $18,866.29 | 2019-2022 | |
| Incyte Corporation | $16,501.43 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $7,597.31 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $6,554.05 | 2019-2024 | Keytruda |
| Janssen Biotech, INC. | $4,630.36 | 2019-2024 | Rybrevant, Carvykti, Talvey |
| Pharmacosmos Therapeutics INC. | $2,672.77 | 2023 | Monoferric |
| Genzyme Corporation | $1,859.02 | 2019-2022 | |
| Karyopharm Therapeutics INC. | $1,509.55 | 2021 | |
| Daiichi Sankyo INC. | $713.29 | 2019-2024 | Enhertu |
| Acceleron Pharma, INC. | $668.30 | 2021 | |
| Astellas Pharma US INC | $530.68 | 2019-2025 | Padcev |
| Astrazeneca Pharmaceuticals LP | $336.25 | 2019-2024 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $317.80 | 2019-2022 | |
| Global Blood Therapeutics, INC. | $248.96 | 2020-2022 | |
| Seagen INC. | $223.29 | 2020-2022 |
Show all 59 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Suh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.